The BMJ
Less than half of approved first indications for new drugs in the US and Europe between 2011 and 2020 were rated as having high therapeutic value, finds new study https://www.bmj.com/content/382/bmj-2022-074166
The BMJ
Less than half of approved first indications for new drugs in the US and Europe between 2011 and 2020 were rated as having high therapeutic value, finds new study https://www.bmj.com/content/382/bmj-2022-074166